|
|||||
|
|
| TRAIL-R激动性抗体的临床研究进展 | |
| 引用本文： | 张妍,;陈曦,;彭永海,;欧阳学农. TRAIL-R激动性抗体的临床研究进展[J]. 临床肿瘤学杂志, 2014, 19(7): 654-661 |
| 作者姓名： | 张妍, 陈曦, 彭永海, 欧阳学农 |
| 作者单位： | 350025.福州南京军区福州总医院肿瘤科 |
| 摘 要： | 肿瘤坏死因子相关凋亡配体受体（TRAIL-R）是TRAIL介导细胞凋亡的重要结合靶点，其中TRAIL-R1和TRAIL-R2（即死亡受体4和死亡受体5）是与诱导细胞凋亡最直接相关的受体，也是最具有开发前景的药物设计靶点。本文对TRAIL-R及其抗体的临床前和临床研究作全面综述，为探索TRAIL介导的抗肿瘤治疗进一步研究提供参考。 |
| 关 键 词： | 肿瘤坏死因子相关凋亡配体受体 TRAIL-R1 TRAIL—R2 细胞凋亡 抗体 |
| 收稿时间： | 2013-08-26 |
| 修稿时间： | 2013-10-28 |
Clinical research advance of TRAIL-R agonistic antibodies |
|
| ZHANG Yan,CHEN Xi,PENG Yonghai,OUYANG Xuenong.. Clinical research advance of TRAIL-R agonistic antibodies[J]. Chinese Clinical Oncology, 2014, 19(7): 654-661 | |
| Authors: | ZHANG Yan CHEN Xi PENG Yonghai OUYANG Xuenong. |
| Affiliation: | Department of Oncology，Fuzhou General Hospital of Nanjing Command，Fujian Medical University，Fuzhou 350025，China |
| Abstract: | Tumor necrosis factor-related apoptosis-inducing ligand receptor（TRAIL-R）, one of important binding targets of TRAIL-mediated apoptosis, including TRAIL-R1 and TRAIL-R2（ ie, death receptor 4 and death receptor 5） not only directly relates to the induction of apoptosis receptors, but also one of the most promising targets for drug design. We carried out a comprehensive review of these antibodies？preclinical and clinical studies to explore the TRAIL-mediated anti-tumor therapy and provide references for further study. |
| Keywords: | Tumor necrosis factor-related apoptosis ligand TRAIL-R1 TRAIL-R2 Apoptosis Antibody |
| 本文献已被 维普 等数据库收录！ | |
| 点击此处可从《临床肿瘤学杂志》浏览原始摘要信息 | |
| 点击此处可从《临床肿瘤学杂志》下载免费的PDF全文 | |